person · Reporting owner

LEDGER STEVEN A

Disclosed activity across 1 company

Tapewire entity: 43932
SEC CIK: 0001090206

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Serina Therapeutics, Inc.SER · Entity 9581	Director · Chief Executive Officer	May 26, 2026	May 27, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Serina Therapeutics, Inc.

Report date May 26, 2026 · Filed May 27, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,100	Reported balance After 2026-05-26 transaction · row 1 1 source row Row 1 · 2026-05-26 · Grant · Acquired 10,100 · Balance 10,100 F1: The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.87 per share to a high purchase price of $1.95 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.

Filing footnotes · ownership attribution and instrument terms

F1: The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.87 per share to a high purchase price of $1.95 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 26, 2026 Filed May 27, 2026 19:55 UTC	Serina Therapeutics, Inc. SER · Entity 9581	GrantCommon Stock	10,100	$1.93	$19,493.00	Disclosure SEC source: 0001090206-26-000007 · wk-form4_1779911715.xml · nonDerivative · entry 1 LEDGER STEVEN A · CIK 0001090206 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,100 F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.87 per share to a high purchase price of $1.95 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price. Read SEC document
May 21, 2026 Filed May 26, 2026 23:37 UTC	Serina Therapeutics, Inc. SER · Entity 9581	GrantStock Option (right to buy) · Derivative	380,825	$0.00 Strike: $1.89	$0.00	Disclosure SEC source: 0001090206-26-000005 · wk-form4_1779838635.xml · derivative · entry 1 LEDGER STEVEN A · CIK 0001090206 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,825 Underlying: Common Stock · 380,825 shares Expires 2036-05-21 F1 · derivative.exercise_date: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. Read SEC document
February 03, 2026 Filed Feb 17, 2026 13:20 UTC	Serina Therapeutics, Inc. SER · Entity 9581	GrantStock Option (right to buy) · Derivative	230,100	$0.00 Strike: $2.76	$0.00	Disclosure SEC source: 0001090206-26-000003 · wk-form4_1771334433.xml · derivative · entry 1 LEDGER STEVEN A · CIK 0001090206 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,100 Underlying: Common Stock · 230,100 shares Expires 2036-02-03 F1 · derivative.exercise_date: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. Read SEC document
March 28, 2025 Filed Apr 1, 2025 20:06 UTC	Serina Therapeutics, Inc. SER · Entity 9581	OtherCommon Stock	95,730	$0.00	$0.00	Disclosure SEC source: 0001628280-25-015888 · wk-form4_1743537960.xml · nonDerivative · entry 1 LEDGER STEVEN A · CIK 0001090206 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,730 F1 · kind: Pro rata distribution from Ki Partners LLC, of which the Reporting Person is a manager. F2 · balance_after: In prior reports, the Reporting Person reported beneficial ownership of 227,927 shares of the Issuers common stock held by Ki Partners LLC. Read SEC document
September 09, 2024 Filed Sep 11, 2024 20:30 UTC	Serina Therapeutics, Inc. SER · Entity 9581	GrantStock Option (right to buy) · Derivative	376,388	$0.00 Strike: $7.40	$0.00	Disclosure SEC source: 0001493152-24-035804 · ownership.xml · derivative · entry 1 LEDGER STEVEN A · CIK 0001090206 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 490,350 Underlying: Common Stock · 376,388 shares Expires 2034-09-09 F1 · derivative.exercise_date: The stock options vest as to 12.5% of the underlying shares on March 9, 2025 and thereafter in substantially equal monthly installments such that the stock options shall be fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.